Printer Friendly

THOMAS WIGGANS NAMED CHIEF OPERATING OFFICER OF CYTOTHERAPEUTICS

 THOMAS WIGGANS NAMED CHIEF OPERATING OFFICER OF CYTOTHERAPEUTICS
 PROVIDENCE, R.I., Jan. 27 /PRNewswire/ -- CytoTherapeutics, Inc. (formerly Cellular Transplants, Inc.) announced today that Thomas G. Wiggans has accepted the position of chief operating officer. CytoTherapeutics is developing encapsulated cell products to treat a variety of chronic and disabling diseases.
 Wiggans' career includes five years with Eli Lilly and more than 10 years with the Ares-Serono Group. He was general manager of Serono's U.S. subsidiary from 1985 to 1990, and served most recently as general manager of Serono Laboratories UK. He holds a B.S. in pharmacy from the University of Kansas, and an M.B.A. from Southern Methodist University.
 "Tom Wiggans brings to the company extensive U.S. and international pharmaceutical industry experience,'' said Seth Rudnick, M.D., CytoTherapeutics' President and CEO. "He has managed high-growth companies and the marketing of innovative healthcare products. We look forward to working with him in building our company, particularly our sales and marketing efforts."
 CytoTherapeutics' CRIB(tm) system encapsulates living cells in a selectively permeable membrane capsule that, when implanted in a host, renders the cells "invisible" to the immune system. At the same time, the membrane allows nutrients from the body to reach the cells and allows therapeutic molecules produced by them to be secreted into the body.
 NeuroCRIB(tm), CytoTherapeutics' first product, is currently in preclinical development as treatment for Parkinson's disease. Clinical trials for NeuroCRIB are scheduled to begin in late 1992. Other applications of the cell implant technology include treatment of neurological disorders, diabetes and enzyme deficiencies.
 CytoTherapeutics, Inc. (formerly Cellular Transplants, Inc.) is developing patentable membrane products to treat a variety of chronic and disabling diseases through the implantation of encapsulated living cells and tissues. These encapsulated living cells, protected from the body's immune system by the membrane, have the potential to replace a wide range of missing or deficient proteins, neurotransmitters, or other molecules critical to health. CytoTherapeutics' initial products, based on the company's proprietary CRIB membrane technology, are targeted for the treatment of Parkinson's disease and Type I diabetes. The company is based in Providence, R.I.
 -0- 1/27/92
 /CONTACT: Erika Karplus of CytoTherapeutics, 401-272-3310; or Lori Martin of Feinstein Partners, 617-577-8110, for CytoTherapeutics/ CO: CytoTherapeutics, Inc. ST: Rhode Island IN: MTC SU: PER


DD-EG -- NE010 -- 3675 01/27/92 11:06 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1992
Words:391
Previous Article:P. A. BERGNER & CO. REPORTS $34.6 MILLION OPERATING PROFIT FOR DECEMBER 1991
Next Article:FASTENAL ANNOUNCES STATEMENT OF EARNINGS
Topics:


Related Articles
DR. MARJORIE CHRISTIE APPOINTED DIRECTOR OF REGULATORY SCIENCES AT CYTOTHERAPEUTICS
DONALD R. CONKLIN JOINS BOARD AT CYTOTHERAPEUTICS
CYTOTHERAPEUTICS ELECTS DANIEL GEFFKEN CHIEF FINANCIAL OFFICER

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters